GlobeNewsWire
29 Jun 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Akari Therapeutics raised approximately $8.3 million in total capital during Q2 2026 through a PIPE and warrant exercises. — Secures immediate runway for a small-cap biotech, reducing near-term liquidity risk and supporting operational continuity.
+0.40The company has initiated IND-enabling studies for its lead candidate AKTX-101 with a goal of starting first-in-human trials by mid-2027. — Provides a concrete clinical timeline for the lead asset, though the target date is over a year away.
+0.30The company is seeking strategic partnerships to advance its proprietary PH1 RNA splicing modulator ADC payload. — Indicates a desire for external validation and non-dilutive funding, though no partner has been named yet.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company successfully completed a PIPE and warrant exercises, securing $8.3 million in capital to advance clinical trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1d ago
